AnswersPublished19 sources
Merck and Moderna’s Personalized Melanoma Vaccine Cut Recurrence Risk 42% in Phase 3
In 1,137 patients with resected stage IIB–IV melanoma, intismeran plus Keytruda reduced the hazard of recurrence or death by 42% after a median 24.6 months of follow up (HR 0.58); this is not a 42 point survival gain... At two years, recurrence free survival was 82.2% with the combination and 70.0% with Keytruda alone.
Published byEdited with GPT-6 LunaImages generated with GPT Image 2
Research answer
Key takeaways
- In 1,137 patients with resected stage IIB–IV melanoma, intismeran plus Keytruda reduced the hazard of recurrence or death by 42% after a median 24.6 months of follow up (HR 0.58); this is not a 42 point survival gain...
- At two years, recurrence free survival was 82.2% with the combination and 70.0% with Keytruda alone.
AI Prompt
openai.comCreate a landscape editorial hero image for this Studio Global article: What did Merck and Moderna’s INTerpath-001 Phase 3 trial—the first successful large randomized trial of a personalized mRNA cancer vaccine—s. Article summary: INTerpath-001 showed that adding intismeran autogene to Keytruda reduced melanoma recurrence or death compared with Keytruda alone after surgery—a positive Phase 3 efficacy result.[8][14] However, the available search ex. Topic tags: general, general web, academic. Style: premium digital editorial illustration, source-backed research mood, clean composition, high detail, modern web publication hero. Use reference image context only for broad subject, composition, and topical grounding; do not copy the exact image. Avoid: logos, brand marks, copyrighted characters, real person likenesses, fake screenshots, UI text, readable text, watermarks, charts with fake num
INTerpath-001 found that adding the personalized mRNA therapy intismeran autogene to Keytruda reduced the risk of melanoma recurrence or death after surgery, compared with Keytruda alone. The Phase 3 trial enrolled 1,137 people with completely resected stage IIB–IV melanoma; after a median 24.6 months, the combination lowered the event hazard by 42% (hazard ratio [HR] 0.58).3 The result is a meaningful recurrence-free-survival finding in this group—not evidence that the treatment cures melanoma or improves overall survival.
What the Phase 3 trial found
The study compared intismeran plus pembrolizumab (Keytruda) with placebo plus pembrolizumab. At the primary analysis, recurrence-free-survival events were reported in 136 patients in the combination group (18.0%) and 111 in the comparison group (29.2%). The estimated hazard ratio was 0.58, with a 95% confidence interval of 0.45–0.75 and P < .001.3
Two-year recurrence-free survival was 82.2% with intismeran plus Keytruda and 70.0% with Keytruda alone—a difference of 12.2 percentage points.11 The trial also found a 38% lower hazard of distant metastasis or death with the combination (HR 0.62; 95% CI 0.45–0.85).
3
A reported analysis among patients who remained recurrence-free beyond six months found a 58% lower hazard of recurrence or death (HR 0.42).13 That result describes a subgroup defined by remaining recurrence-free through that period; it should not be mistaken for the overall trial result, which was HR 0.58.
3
What “42% lower risk” means
The 42% figure is a relative reduction in the hazard of recurrence or death over the follow-up period, not a 42-percentage-point increase in the number of people who remained recurrence-free. The two-year rates offer a separate absolute comparison: 82.2% versus 70.0%.3
11
What the results do—and do not—establish
INTerpath-001 tested whether adding intismeran to Keytruda improved outcomes for people with resected high-risk melanoma. It did. But the results reported here do not establish that the combination extends overall survival; overall-survival follow-up is continuing.58
Intismeran is described as an individualized neoantigen therapy, designed around features of a patient’s tumor.14 The clinical comparison shows the benefit of adding the treatment to Keytruda, but by itself does not determine how much of that benefit comes from tumor-specific immune recognition or explain the precise biological mechanism.
The findings are also specific to the population studied: patients with completely resected stage IIB–IV melanoma. They do not prove that personalized cancer vaccines will work in other tumor types or stages. Further research is needed to assess where else the approach may help.3
50
What happens next
The detailed results were reported as accepted for publication in The New England Journal of Medicine.51 They became public ahead of the planned October 24, 2026, ESMO presentation after an embargo breach; reports described the early disclosure on October 22.
6
12
The central takeaway is encouraging but bounded: adding intismeran to Keytruda improved recurrence-free outcomes in a large Phase 3 melanoma trial. Longer follow-up will be needed to clarify overall survival, while studies in other cancers will be needed before the result can be generalized beyond this setting.
Studio Global AI
Continue your research
This page includes a source-backed answer you can continue inside Studio Global.
People also ask
What is the short answer to "Merck and Moderna’s Personalized Melanoma Vaccine Cut Recurrence Risk 42% in Phase 3"?
In 1,137 patients with resected stage IIB–IV melanoma, intismeran plus Keytruda reduced the hazard of recurrence or death by 42% after a median 24.6 months of follow up (HR 0.58); this is not a 42 point survival gain...
What are the key points to validate first?
In 1,137 patients with resected stage IIB–IV melanoma, intismeran plus Keytruda reduced the hazard of recurrence or death by 42% after a median 24.6 months of follow up (HR 0.58); this is not a 42 point survival gain... At two years, recurrence free survival was 82.2% with the combination and 70.0% with Keytruda alone.